Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
304 injection
- Development stage
- Phase 3
- Lead developer
- 3S Guojian Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Injection
01
Overview
304 injection is a recombinant human-mouse chimeric anti-CD20 monoclonal antibody developed by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. It is a biosimilar to rituximab and is being investigated for the treatment of CD20 positive B-cell non-Hodgkin lymphoma. Its mechanism of action involves targeting the CD20 antigen on B-lymphocytes, leading to B cell depletion through processes like antibody-dependent cell cytotoxicity.
- Brand names
- Retuxira
- Other names
- recombinant human-mouse chimeric anti-CD20 monoclonal antibody
02
Targets
Beyond the preview
Go deeper on 304 injection.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 304 injection.